Welcome to our dedicated page for Royalty Pharma Plc news (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma Plc stock.
Royalty Pharma plc (Nasdaq: RPRX) is the leading acquirer of revenue-producing intellectual property, primarily focusing on royalty interests in marketed and late-stage biopharmaceutical products. Established in 1996, the company has built a robust portfolio with over $13 billion in assets and has invested nearly $5.8 billion to date. Royalty Pharma excels in acquiring and managing diverse royalty interests across various therapeutic areas, mitigating the common risks associated with biopharmaceutical investments.
Royalty Pharma's portfolio includes royalties on more than 35 commercial products, such as AbbVie and Johnson & Johnson's Imbruvica for blood cancers, Biogen's Tysabri for multiple sclerosis, and Vertex's cystic fibrosis drugs. The company also holds interests in 14 development-stage products, demonstrating its commitment to funding innovation in the biopharmaceutical sector.
Recent achievements include a $525 million acquisition of royalties and milestones on frexalimab, a promising therapy developed by Sanofi for multiple sclerosis and other immune-mediated diseases. This transaction enhances Royalty Pharma's development-stage portfolio, reinforcing its potential for long-term growth.
Financially, Royalty Pharma reported first-quarter 2024 results reflecting strong royalty receipts growth, driven by key therapies like Trelegy and Vertex’s cystic fibrosis franchise. The company maintains a solid liquidity position with $843 million in cash and cash equivalents and a total debt of $6.3 billion.
Royalty Pharma's strategic partnerships span a broad spectrum of innovators, from academic institutions and research hospitals to leading global pharmaceutical companies. This extensive collaboration network underscores the company's pivotal role in advancing medical research and providing essential funding for late-stage clinical trials and new product launches.
For more information, visit www.royaltypharma.com.
Royalty Pharma (RPRX) announced it will report its Q4 and full year 2022 financial results on February 15, 2023, before the U.S. markets open. The company will host a conference call at 8:00 a.m. ET to discuss the results. Royalty Pharma specializes in acquiring biopharmaceutical royalties and funding innovation across the industry, supporting numerous therapies through its extensive portfolio of royalties from over 35 commercial products, such as Vertex’s Trikafta and Biogen’s Tysabri. For further details, visit their Investors page.
Royalty Pharma (RPRX) has reported a strong operational performance for 2022, forecasting Net cash provided by operating activities of approximately $2.14 billion to $2.15 billion and Adjusted Cash Receipts of $2.785 billion to $2.79 billion, marking a 31% year-over-year growth. The company has achieved significant capital deployment, announcing $10 billion in transactions since 2020, projected to contribute $1 billion to future receipts. Management emphasizes resilience amid revenue declines in key areas, positioning for innovation and growth.
Royalty Pharma (RPRX) announced its acquisition of an interest in SPINRAZA® and pelacarsen royalties from Ionis Pharmaceuticals. The deal totals up to $1.125 billion, including a $500 million upfront payment and up to $625 million in milestone payments. Ionis retains a majority of the royalties and milestone payments for pelacarsen, expected to advance its late-stage programs and innovative pipeline. This partnership aims to enhance the commercial readiness of Ionis’s therapies targeting spinal muscular atrophy and cardiovascular diseases.
Ionis Pharmaceuticals has announced a significant royalty agreement with Royalty Pharma, involving an upfront payment of $500 million and potential milestones of up to $625 million. This deal allows Royalty Pharma to acquire an interest in Ionis' royalties from SPINRAZA and pelacarsen, while Ionis retains the majority of royalties and milestone payments from Novartis. The investment aims to bolster Ionis' late-stage programs and innovative genetic medicines pipeline, highlighting confidence in the commercial potential of both therapies.
Royalty Pharma plc (Nasdaq: RPRX) has declared a quarterly dividend of $0.20 per Class A share for the first quarter of 2023, marking a 5.3% increase from the previous quarter. The dividend will be paid on March 15, 2023, to shareholders of record as of February 16, 2023. CEO Pablo Legorreta emphasized the company's commitment to returning capital to shareholders while maintaining financial flexibility for future innovations, noting strong demand for capital in the biopharma sector.
Royalty Pharma, listed on Nasdaq as RPRX, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET. The presentation can be accessed via the company's Events page and will be archived for at least 30 days. Founded in 1996, Royalty Pharma is a leader in biopharmaceutical royalties, funding innovation through collaborations with various biopharmaceutical entities. Its portfolio includes royalties from over 35 commercial products.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a $25 million milestone payment from Amgen (NASDAQ: AMGN) triggered by the enrollment of the first subject in Amgen's Phase 3 trial of olpasiran. Arrowhead is also in line to receive up to $535 million in additional milestone payments from Amgen and Royalty Pharma (NASDAQ: RPRX). The olpasiran therapy targets lipoprotein(a) to reduce cardiovascular disease risk. This milestone represents significant progress for Arrowhead, being the second TRiM-enabled candidate to enter Phase 3 trials, with more projected to follow in the coming year.
Royalty Pharma plc (Nasdaq: RPRX) has announced key promotions within its senior leadership team effective January 1, 2023. Sara Klymkowsky and Brienne Kugler are promoted to Senior Vice President, Research & Investments, recognized for their significant contributions to major transactions since they joined the company in 2012 and 2014, respectively. Alessandra Sassun is appointed Senior Vice President, Head of Human Capital, bringing experience in human resources. CEO Pablo Legorreta expressed confidence that this strengthened leadership will enhance Royalty Pharma's mission in life sciences innovation and stakeholder value.
Royalty Pharma plc (Nasdaq: RPRX) is set to join the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 30, 2022, at 10:30 a.m. ET. Investors can access the live webcast via Royalty Pharma’s “Events” page, where it will be archived for at least 30 days.
Royalty Pharma, founded in 1996, specializes in acquiring biopharmaceutical royalties. The company collaborates with various innovators across the biopharmaceutical sector and currently holds royalties for over 35 commercial products, enhancing the funding of innovation within the industry.
Royalty Pharma (Nasdaq: RPRX) has acquired a royalty interest in Amgen's olpasiran from Arrowhead Pharmaceuticals for $250 million in cash, with potential additional payments up to $160 million based on certain milestones. Olpasiran, developed to reduce lipoprotein(a) levels associated with cardiovascular diseases, has shown promise in Phase 2 studies. Arrowhead retains rights to $400 million in milestone payments from Amgen. This acquisition reinforces Royalty Pharma's strategy to invest in innovative therapies targeting unmet medical needs.
FAQ
What is the current stock price of Royalty Pharma Plc (RPRX)?
What is the market cap of Royalty Pharma Plc (RPRX)?
What does Royalty Pharma do?
What are some key products in Royalty Pharma’s portfolio?
How does Royalty Pharma fund innovation?
What is the company's financial position?
What recent acquisitions has Royalty Pharma made?
How does Royalty Pharma mitigate risks?
Who are Royalty Pharma’s partners?
What are Royalty Pharma’s recent financial results?
What is Royalty Pharma’s strategy?
Where can I find more information about Royalty Pharma?
